News archive
August 2026
-
Statement
FDA updates LEQVIO® label
-
Media Release
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goals New AZALEA-TIMI 71 analyses will further characterize the bleeding… -
Story Education and Awareness
New Heart Health Information Patients Need to Know: Understanding the 2026 Cholesterol Guidelines
Younos Abdulsattar, PharmD, a Novartis medical team leader, breaks down the 2026 cholesterol guidelines, and what patients need to know about LDL-C, Lp(a), and heart health.
-
Story Medicines
![Several people working at assembling the big letters forming "Novartis" that will be installed at the top of a building on the Novartis Basel campus](/us-en/sites/novartis_us/files/styles/list_view_image_660_370/public/2026-07/novartis-merger-1996-building-letters-media-content.jpg.webp?itok=X75DXUhA "Several people working at assembling the big letters forming "Novartis" that will be installed at the top of a building on the Novartis Basel campus")
Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next
The roots of Novartis reach back more than 250 years, to the chemical and scientific traditions that helped shape modern healthcare. Thirty years after its creation, a legacy of discovery and curiosity continues to guide its pursuit of new possibilities for patients.
July 2026
-
Media Release
FDA approves Pluvicto® for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient population PSMAddition updated results show Pluvicto reduced risk of progression or death by… -
Media Release
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks,… -
Story Medicines Immunology
The Future of Autoimmune Disease: A Q&A You Need to Read
1 in 5 Americans lives with an autoimmune disease, yet many have no or very limited treatment options. Christy Siegel, SVP and TA Head, Immunology, Novartis US, shares how we aim to change that.
-
Story Medicines
Meet Colin: A Novartis Scientist Looking for New Breakthroughs
Colin works on a cryo-electron microscope the size of a room using a process that earned a team of scientists a Nobel Prize. Learn how his work is advancing the ways we treat disease.
June 2026
-
Story Education and Awareness
Carrie Ann Inaba: “I Wouldn’t Be Who I Am Without Sjögren's Disease"
For World Sjögren's Day, dancer and TV personality Carrie Ann Inaba shares her story of diagnosis, living with the disease, and self-advocacy
-
Media Release
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile and no observed liver safety… -
Media Release
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous resultsDel-brax indicates potential to become… -
Media Release
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted …